Automated, aseptic sampling with small-volume capacity from microbioreactors for cell therapy process analysis

Zhi Xian Chan¹Shruthi Pandi Chelvam¹Wei-Xiang Sin¹Denise Bei Lin Teo¹Ahmad Amirul Abdul Rahim²Ying Ying Wu²Dan Liu²Michael Birnbaum¹Derrick Yong¹Rajeev Ram^1*

• ¹Singapore-MIT Alliance for Research and Technology (SMART), Singapore, Singapore
• ²Bioprocessing Technology Institute (A*STAR), Singapore, Singapore

Current workflows in autologous cell therapy manufacturing are reliant on manual processes that are difficult to scale out to meet patient demands. High throughput bioreactor systems that enable multiple cultures to occur in parallel can address this need, but require good bioprocess monitoring workflows to produce good quality cell therapy products. Commercial sampling systems have thus been developed for better feedback control and monitoring capabilities. However, they are targeted towards large scale processes and often bioreactor specific, making them less robust for integration across different bioreactor scales and types, such as perfusion-capable microbioreactors which allows for greater process intensification. Here, an automated cell culture sampling system (Auto-CeSS) was developed to eliminate laborious manual sampling while minimizing sterility risks for cell therapy manufacturing processes. The system is aseptically integrated with a variety of bioreactors of different working volumes. This system can accurately and aseptically sample a minimum volume of 30 μL and can consistently perform periodic sampling of supernatant over a minimum interval of 15 minutes. We integrated Auto-CeSS with a 2 mL perfusion microbioreactor and a 8 mL gaspermeable well-plate for T cell culture, collecting 200 μL of supernatant samples daily for metabolite analysis. Comparison of the metabolic profiles of the samples collected via Auto-CeSS versus manual sampling revealed insignificant differences in metabolite levels, including glucose, lactate, glutamine, and glutamate. This report demonstrates the potential of Auto-CeSS as an at-line sampling platform in a real-time T cell production run to facilitate in-process culture monitoring.